Anbio Biotechnology
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| – | +6.4% | -79.8% | +131.6% | -423.9% | |
| – | – | +92.9% | -100.0% | – | |
| – | -436.0% | – | – | -29,689.5% | |
| – | – | -100.0% | – | – | |
| – | – | – | -80.5% | -1,346.7% | |
| – | – | – | +704.5% | – | |
| – | -30.1% | -11.5% | -19.8% | -292.7% | |
| – | +6.4% | -79.8% | +131.6% | -423.9% |
Data as of: September 29, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.